@article{765ceef18c294adabb99ed19c6a53466,
title = "Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease",
abstract = "Active inflammation during pregnancy in women with inflammatory bowel disease (IBD) is a risk factor for clinical relapse. 1,2 In utero exposure to biologics is not associated with adverse pregnancy outcomes 3 or infections in infants born to mothers with IBD. 1,2,4 However, prior studies did not account for day care exposure in the first year of life, which is an established risk factor for infection in the general population. We aimed to determine whether children born to mothers with IBD have an increased rate of infection when attending day care in the first year after exposure to biologic therapy in utero. ",
keywords = "Child, Day Care, Medical, Female, Humans, Infant, Inflammatory Bowel Diseases/complications, Mothers, Pregnancy, Pregnancy Complications/drug therapy, Prenatal Exposure Delayed Effects/drug therapy",
author = "Long, {Millie D.} and Siegel, {Corey A.} and Abraham, {Bincy P.} and Michael Chiorean and Uma Mahadevan",
note = "Funding Information: Funding Supported by Crohn's and Colitis Foundation and National Institutes of Health (P30 DK034987). Conflicts of interest The authors disclose the following: Millie D. Long reports consulting for Takeda, Pfizer, AbbVie, UCB, Janssen, Prometheus, Salix, Valeant, and Target Pharmasolutions; and grant support from Takeda and Pfizer. Corey A. Siegel reports consulting for AbbVie, Amgen, Celgene, Lilly, Janssen, Sandoz, Pfizer, Prometheus, Sebela, and Takeda; and grant support from AbbVie, Janssen, Pfizer, and Takeda. Bincy P. Abraham reports consulting for Pfizer, Samsung Bioepis, Medtronic, Janssen, UCB, and Takeda; research for Takeda and Janssen; and Speaker's Bureau for Janssen, UCB, AbbVie, Takeda, and Pfizer. Michael Chiorean has a relationship with Takeda, Janssen, AbbVie, Pfizer, Prometheus, Arena, Medtronic, and BMS (Bristol-Meyer-Squibb). Uma Mahadevan reports consulting for AbbVie, Janssen, Takeda, BMS, and Gilead; and research for Pfizer, Celgene, and Genentech. Funding Information: Funding Supported by Crohn{\textquoteright}s and Colitis Foundation and National Institutes of Health ( P30 DK034987 ). ",
year = "2022",
month = mar,
doi = "10.1016/j.cgh.2021.02.003",
language = "English (US)",
volume = "20",
pages = "706--708.e1",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "3",
}